NewswireToday - /newswire/ -
London, United Kingdom, 2017/10/05 - BTG plc announces it has acquired Roxwood Medical (“Roxwood”), an innovative provider of advanced cardiovascular specialty catheters used in the treatment of patients with severe coronary and peripheral artery disease - RoxwoodMedical.com / BTGplc.com. LSE: BTG
BTG plc, the global specialist healthcare company, today announces it has acquired Roxwood Medical (“Roxwood”), an innovative provider of advanced cardiovascular specialty catheters used in the treatment of patients with severe coronary and peripheral artery disease.
Roxwood's anchoring catheters (CenterCross®, CenterCross® Ultra, MultiCross®) and microcatheters (MicroCross®) offer options for physicians in the crossing of complex lesions and arterial blockages. By incorporating a self-expanding scaffold that stabilizes the delivery of a guidewire, Roxwood’s catheters provide positioning accuracy and support to facilitate the crossing of blockages, mitigating guidewire buckling and enabling treatments such as angioplasty, stenting or atherectomy.
“This bolt-on acquisition continues to build BTG’s strength in the interventional vascular space, further expanding our portfolio of differentiated minimally invasive vascular technologies,” said John Sylvester, BTG’s Chief Commercial Officer. “Roxwood’s products complement our existing business and will be offered through our existing EKOS® hospital sales force, providing our customers with options to enable treatment of these patients with complex lesions.”
“This is an exciting new chapter for the team at Roxwood and further testament to the utility of the anchoring and microcatheter platforms,” said Mehrdad Farhangnia, Roxwood’s Chief Executive Officer. “With the expanded commercial and clinical reach of BTG, these minimally invasive tools can help far more clinicians successfully treat patients with severe arterial blockages.”
BTG will pay up to $80m in cash to acquire Roxwood, comprising $65m paid on closing and up to an additional $15m should certain future commercial milestones be achieved. The transaction is expected to be accretive to adjusted EPS from the second full year of ownership.
BTG (btgplc.com) is a global specialist healthcare company bringing to market innovative products in specialist areas of medicine to better serve doctors and their patients. We have a portfolio of Interventional Medicine products to advance the treatment of cancer, severe emphysema, severe blood clots and varicose veins, and Specialty Pharmaceuticals that help patients overexposed to certain medications or toxins. Inspired by patient and physician needs, BTG is investing to expand its portfolio to address some of today’s most complex healthcare challenges.
Andy Burrows, VP Corporate & Investor Relations
P: +44(0)20 7575 1741 / M: +44(0)79 9053 0605
Stuart Hunt, Investor Relations Manage
P: +44(0)20 7575 1582 / M: +44(0)78 1577 8536
FTI Consulting: Ben Atwell / Simon Conway
P: +44(0)20 3727 1000